Compare EKSO & JSPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EKSO | JSPR |
|---|---|---|
| Founded | 2005 | 2018 |
| Country | United States | United States |
| Employees | N/A | 64 |
| Industry | Medical/Dental Instruments | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 37.9M | 34.7M |
| IPO Year | 2012 | N/A |
| Metric | EKSO | JSPR |
|---|---|---|
| Price | $10.01 | $1.06 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 2 | 11 |
| Target Price | $9.50 | ★ $16.28 |
| AVG Volume (30 Days) | 70.0K | ★ 271.7K |
| Earning Date | 05-04-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 41.76 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $81.23 | N/A |
| Revenue Next Year | $7.29 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.23 | $1.07 |
| 52 Week High | $13.50 | $7.19 |
| Indicator | EKSO | JSPR |
|---|---|---|
| Relative Strength Index (RSI) | 43.96 | 30.24 |
| Support Level | $9.64 | N/A |
| Resistance Level | $10.76 | $1.44 |
| Average True Range (ATR) | 0.90 | 0.07 |
| MACD | -0.18 | -0.02 |
| Stochastic Oscillator | 0.00 | 5.41 |
Ekso Bionics Holdings Inc designs, develops and sells exoskeleton technology used in healthcare and industrial markets. The wearable exoskeletons are to be worn over clothes and controlled by a trained operator to augment human strength, endurance, and mobility. The company's segments are Enterprise Health and Personal Health. All of the company's operations are held in the United States. The regions the company operates in are the Americas, EMEA, and APAC.
Jasper Therapeutics Inc is a clinical-stage biotechnology company dedicated to enabling cures through hematopoietic stem cell therapy. It is focused on the development and commercialization of safer and more effective conditioning agents and stem cell engineering to allow for expanded use of stem cell transplantation and ex vivo gene therapy.